Immatics N.V. (IMTX) NASDAQ

10.18

+0.05(+0.49%)

Updated at October 23 04:00PM

Currency In USD

Immatics N.V.

Address

Paul-Ehrlich-Strasse 15

Tübingen, 72076

Germany

Phone

49 7071 5397 0

Sector

Healthcare

Industry

Biotechnology

Employees

554

First IPO Date

December 12, 2018

Key Executives

NameTitlePayYear Born
Dr. Harpreet Singh Ph.D.Chief Executive Officer, MD, Member of Management Board & Executive Director931,8191975
Dr. Carsten Reinhardt M.D., Ph.D.Chief Development Officer01967
Mr. Edward A. SturchioGeneral Counsel & Secretary0N/A
Dr. Toni Weinschenk Ph.D.Co-Founder & Chief Innovation Officer01974
Mr. Cedrik M. Britten M.D.Chief Medical Officer01976
Mr. Jordan SilversteinHead of Strategy01980
Dr. Hans-Georg Rammensee Ph.D.Co-Founder & Member of the Scientific Advisory Board0N/A
Mr. Arnd Christ MBAChief Financial Officer01966
Mr. Steffen Walter Ph.D.Chief Operations Officer01977
Dr. Rainer Kramer Ph.D.Chief Business Officer & Site Head Munich01965

Description

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.